Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

PD-L1 positivity by Ventana SP142 assay

KS Katherine Sanchez
IK Isaac Kim
BC Brie Chun
JP Joanna Pucilowska
WR William L. Redmond
WU Walter J. Urba
MM Maritza Martel
YW Yaping Wu
MC Mary Campbell
ZS Zhaoyu Sun
GG Gary Grunkemeier
SC Shu Ching Chang
BB Brady Bernard
DP David B. Page
ask Ask a question
Favorite

Additional 5-μm FFPE slides were stained for clinical PD-L1 scoring using the SP142 assay (Ventana Medical Systems Inc., Tucson, AZ, USA). ICs were scored by two blinded pathologists using published guidelines [6, 20], reported as the proportion of tumor area occupied by PD-L1-staining ICs of any intensity. PD-L1 was scored using the recommended standardized cutoffs (IC0- < 1%, IC1- ≥ 1% to < 5%, IC2 ≥ 5% to 10%, and IC3 ≥ 10%) [6]. In metastatic TNBC, anti-PD-L1 therapy (atezolizumab) is approved in combination with nab-paclitaxel for the treatment of PD-L1 tumors, which corresponds with scores of IC1-IC3 [1, 2]. To serve as internal control for sTIL and PD-L1 score, a contemporary cohort of untreated stage I-III biopsy and matched surgical resection samples (n = 14) were analyzed for PD-L1 and sTIL score.

Copyright and License information: The Author(s) ©2021
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A